A blog about what is new (and old) in the world of active implantable medical devices 

Facebook Twitter Gplus Flickr LinkedIn YouTube RSS
magnify
Home AIMD Business St. Jude’s Q1 2013 AIMD Results: CRM Down 7%, Neuromodulation Down 4%
formats

St. Jude’s Q1 2013 AIMD Results: CRM Down 7%, Neuromodulation Down 4%

logo_StJudeMedical

St. Jude Medical announced sales results for Q1 2013.  AIMD results from their press release:

“Cardiac Rhythm Management (CRM)

Total CRM sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $678 million for the first quarter of 2013, an 8 percent decrease compared to the first quarter of 2012. After adjusting for the impact of foreign currency, total CRM sales decreased 7 percent.

Of that total, ICD product sales were $427 million in the first quarter, a 5 percent decrease compared to the first quarter of 2012. ICD revenue decreased 4 percent after adjusting for the impact of foreign currency.

First quarter pacemaker sales were $251 million, a 12 percent decrease compared to the first quarter of 2012.”

“Neuromodulation

St. Jude Medical sales of neuromodulation products were $99 million in the first quarter of 2013, down 4 percent from the prior year.”

 

 

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on St. Jude’s Q1 2013 AIMD Results: CRM Down 7%, Neuromodulation Down 4%  comments